Madrigal Pharmaceuticals (MDGL) Price & Analysis

Compare

1,325 Followers

MDGL Stock Chart & Stats

$488.26

-$1.78(-0.55%)

At close: Jan 08 4:00 PM EST

$488.26

-$1.78(-0.55%)

Day’s Range― - ―

52-Week Range$265.00 - $615.00

Previous CloseN/A

Volume47.78K

Average Volume (3M)314.95K

Market Cap

$10.85B

Enterprise Value$11.14B

Total Cash (Recent Filing)$1.11B

Total Debt (Recent Filing)$346.40M

Price to Earnings (P/E)―

Beta0.34

Next Earnings

Feb 19, 2026

EPS Estimate

-0.81

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.08

Shares Outstanding22,711,420

10 Day Avg. Volume336,365

30 Day Avg. Volume314,953

Financial Highlights & Ratios

PEG Ratio-1.47

Price to Book (P/B)8.70

Price to Sales (P/S)36.44

P/FCF Ratio-14.36

Enterprise Value/Market Cap1.03

Enterprise Value/Revenue15.04

Enterprise Value/Gross Profit15.79

Enterprise Value/Ebitda-41.24

Forecast

1Y Price Target

$705.56

Price Target Upside44.50% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering11

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Commercial TractionStrong commercial uptake, growing patient starts and broad insurer coverage signal sustained sales momentum and support upward revenue expectations.

Regulatory ApprovalFormal approval of Rezdiffra in the European Union expands market access and supports additional product sales and geographic growth.

Strategic Partnership And Combination PotentialExclusive licensing of a DGAT‑2 inhibitor and plans for drug–drug interaction studies and a factorial combination trial create the potential for additive clinical benefits and a differentiated combination approach.

Bears Say

Competitive Pressure From New EntrantsLabel expansion of GLP‑1 therapies and the prospect of lower-cost GLP‑1s and more potent FGF21 agents could erode Rezdiffra’s market share and limit pricing leverage.

Prescriber Access And Adoption HurdlesPrescriber skepticism about MASH and administrative barriers, including limited access to diagnostic tools, may slow adoption despite positive clinical data.

Safety And Monotherapy Efficacy UncertaintyHistorical limited efficacy of DGAT‑2 monotherapy and class safety concerns raise uncertainty about the success and perceived safety of proposed combination regimens.

Madrigal Pharmaceuticals News

Madrigal Pharmaceuticals price target lowered to $570 from $595 at BofA

BofA lowered the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $570 from $595 and keeps a Neutral...

7d ago

MDGL

Madrigal Pharmaceuticals initiated with an Overweight at Barclays

Barclays initiated coverage of Madrigal Pharmaceuticals (MDGL) with an Overweight rating and $964 price target Barclays initiated coverage...

14d ago

MDGL

Madrigal Pharmaceuticals price target raised to $745 from $527 at Citizens

Citizens raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $745 from $527 and keeps an Outperform...

21d ago

MDGL

Madrigal Pharmaceuticals price target raised to $644 from $554 at TD Cowen

TD Cowen raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $644 from $554 and keeps a...

29d ago

PFE

MDGL

Madrigal Gains Expanded Patent Control Over Rezdiffra With Roche

The latest announcement is out from Madrigal Pharmaceuticals ( ($MDGL) ). On January 29, 2026, Madrigal Pharmaceuticals and...

11d ago

MDGL

Madrigal, Clene, Cencora, Sequans, Amicus: Insider Moves Exposed

Insiders have been trading these 5 stocks: (($MDGL)), (($CLNN)), (($COR)), (($SQNS)) and (($FOLD)). Here is a breakdown of...

17d ago

COR

CLNN

Madrigal: Expanding MASH Franchise and Combination Therapy Strategy Drive Raised Price Target and Reaffirmed Buy Rating

Analyst Ritu Baral from TD Cowen maintained a Buy rating on Madrigal Pharmaceuticals and increased the price target...

30d ago

MDGL

Madrigal Pharmaceuticals expands MASH pipeline with global license agreement

Madrigal Pharmaceuticals (MDGL) announced an exclusive global license agreement with Pfizer (PFE) for ervogastat, a clinical-stage oral DGAT-2...

1M ago

PFE

MDGL

Morning Movers: OneStream surges following report of Hg takeover talks

Stock futures are showing modest movement, reflecting a pause after recent record highs. Traders appear reluctant to push...

1M ago

DHI

Wolfe downgrades Madrigal Pharmaceuticals to Peer Perform on valuation

As previously reported, Wolfe Research analyst Andy Chen downgraded Madrigal Pharmaceuticals (MDGL) to Peer Perform from Outperform and...

1M ago

MDGL

Madrigal Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe Research

Wolfe Research downgraded Madrigal Pharmaceuticals (MDGL) to Peer Perform from Outperform. Published first on TheFly – the ultimate...

1M ago

MDGL

These Are the Most and Least Likely Biotech Takeover Targets for 2026

Abivax ($ABVX), a French biotech firm, has become the top acquisition candidate among biotechs in 2026, according to...

2M ago

LLY

TFC

Short Report: Vera Therapeutics bears retreat as stock rallies

Welcome to this week’s installment of “The Short Interest Report” – The Fly’s weekly recap of short interest...

2M ago

MBLY

MDGL

Madrigal Pharmaceuticals price target raised to $900 from $540 at Piper Sandler

Piper Sandler raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $900 from $540 and keeps an...

2M ago

MDGL

MDGL FAQ

What was Madrigal Pharmaceuticals Inc’s price range in the past 12 months?

Madrigal Pharmaceuticals Inc lowest stock price was $265.00 and its highest was $615.00 in the past 12 months.

What is Madrigal Pharmaceuticals Inc’s market cap?

Madrigal Pharmaceuticals Inc’s market cap is $10.85B.

When is Madrigal Pharmaceuticals Inc’s upcoming earnings report date?

Madrigal Pharmaceuticals Inc’s upcoming earnings report date is Feb 19, 2026 which is in 9 days.

How were Madrigal Pharmaceuticals Inc’s earnings last quarter?

Madrigal Pharmaceuticals Inc released its earnings results on Nov 04, 2025. The company reported -$5.08 earnings per share for the quarter, missing the consensus estimate of -$2.285 by -$2.795.

Is Madrigal Pharmaceuticals Inc overvalued?

According to Wall Street analysts Madrigal Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Madrigal Pharmaceuticals Inc pay dividends?

Madrigal Pharmaceuticals Inc does not currently pay dividends.

What is Madrigal Pharmaceuticals Inc’s EPS estimate?

Madrigal Pharmaceuticals Inc’s EPS estimate is -0.81.

How many shares outstanding does Madrigal Pharmaceuticals Inc have?

Madrigal Pharmaceuticals Inc has 22,711,420 shares outstanding.

What happened to Madrigal Pharmaceuticals Inc’s price movement after its last earnings report?

Madrigal Pharmaceuticals Inc reported an EPS of -$5.08 in its last earnings report, missing expectations of -$2.285. Following the earnings report the stock price went up 7.831%.

Which hedge fund is a major shareholder of Madrigal Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in MDGL

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Madrigal Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-41.22%

Trailing 12-Months

Asset Growth

26.95%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.

Madrigal Pharmaceuticals (MDGL) Earnings & Revenues

Historic Earnings Reports

MDGL Company Deck

MDGL Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call reflects a strong quarter for Madrigal Pharmaceuticals, driven by the successful launch of Rezdiffra and robust financial health. However, increased operating expenses and ongoing challenges with payer contracting highlight areas of concern. Additionally, competitive pressures from other entrants in the MASH market could impact future growth. Overall, the sentiment is cautiously optimistic.View all MDGL earnings summaries

MDGL Stock 12 Month Forecast

Average Price Target

$705.56

▲(44.50% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"271":"$271","618":"$618","965":"$965","444.5":"$444.5","791.5":"$791.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":964,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$964.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":705.56,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$705.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":570,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$570.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[271,444.5,618,791.5,965],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,489.73,526.2123076923077,562.6946153846154,599.1769230769231,635.6592307692308,672.1415384615385,708.6238461538462,745.1061538461538,781.5884615384616,818.0707692307692,854.553076923077,891.0353846153846,927.5176923076923,{"y":964,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,489.73,506.3323076923077,522.9346153846154,539.5369230769231,556.1392307692307,572.7415384615384,589.3438461538461,605.9461538461538,622.5484615384615,639.1507692307691,655.7530769230768,672.3553846153845,688.9576923076922,{"y":705.56,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,489.73,495.9046153846154,502.0792307692308,508.25384615384615,514.4284615384615,520.603076923077,526.7776923076923,532.9523076923077,539.126923076923,545.3015384615385,551.4761538461538,557.6507692307692,563.8253846153846,{"y":570,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":334.8,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":341.27,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":323.98,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.7,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":272.67,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":300.16,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":302.17,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":436.11,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":449.14,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":418.9,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":579.45,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":582.34,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":489.73,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >